High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Background The changes in nonalcoholic fatty liver disease (NAFLD) range over a wide spectrum, extending from steatosis to steatohepatitis (NASH). However, it has remained difficult to differentiate between NASH and nonprogressive NAFLD by clinical examination. We investigated the interrelationships between serum high-sensitivity C-reactive protein (hs-CRP) and the pathogenesis and progression of NASH.Methods Hs-CRP was measured in 100 patients with histologically verified NAFLD (29 with steatosis and 71 with NASH), and a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis was performed to measure the intrahepatic mRNA expressions of CRP and interleukin (IL)-6.Results The results of a multiple regression analysis revealed that in comparison with cases of steatosis, hs-CRP was significantly elevated (P = 0.0048) in cases of NASH. Furthermore, among patients with NASH, hs-CRP was significantly elevated in those with advanced fibrosis compared with that in those with mild fibrosis (P = 0.0384), even after adjustment for age, sex, presence of diabetes, body mass index, visceral fat area, subcutaneous fat area, homeostasis model assessment for insulin resistance, high-density lipoprotein cholesterol, triglyceride, and low-density lipoprotein cholesterol. The results of the RT-PCR analysis showed that intrahepatic mRNA expression of CRP, but not IL-6, was increased in patients with NASH compared with those with steatosis (P = 0.0228).Conclusions This is the first report to demonstrate consistent and profound elevation of hs-CRP in cases of NASH compared with in cases of simple nonprogressive steatosis. Our results suggest that hs-CRP may be a clinical feature that not only distinguishes NASH from simple nonprogressive steatosis but also indicates the severity of hepatic fibrosis in cases of NASH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CRP is predictive of NASH in patients with NAFLD and is related to the presence and severity of liver fibrosis [133].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [133]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Research works printed but not linked: 4
- JM Hui, 2004, Hepatology, 40, 46
- T Ono, 1999, J Jpn Diabetes Soc, 42, 1005
- JM Hui, 2003, Hepatology, 38, 420
- H Baumann, 1990, Mol Biol Med, 7, 147
Cited by
Items 101–200 of 300
Johnson, N. D., Wu, X., Still, C. D., Chu, X., Petrick, A. T., Gerhard, G. S., Conneely, K. N., & DiStefano, J. K. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01129-y · Cited by 43
Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity
Rachakonda, V. P., Reeves, V. L., Aljammal, J., Wills, R. C., Trybula, J. S., DeLany, J. P., Kienesberger, P. C., & Kershaw, E. E. (2015) · Obesity · doi:10.1002/oby.20960 · Cited by 45
Wang, R., Wang, X., & Zhuang, L. (2016) · PubMed · doi:10.5604/16652681.1193709 · Cited by 46
Non-alcoholic steatohepatitis in morbidly obese patients
Tran, A., & Gual, P. (2013) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2012.07.005 · Cited by 45
Pro- and Anti-inflammatory Cytokines in Steatosis and Steatohepatitis
Rabelo, F., de Oliveira, C. P. M. S., Faintuch, J., Mazo, D. F. D. C., de Lima, V. M. R., Stefano, J. T., Barbeiro, H. V., Soriano, F. G., Alves, V. A. F., & Carrilho, F. J. (2010) · Obesity Surgery · doi:10.1007/s11695-010-0181-4 · Cited by 47
Demir, M., Lang, S., Schlattjan, M., Drebber, U., Wedemeyer, I., Nierhoff, D., Becker, I., Sowa, J., Canbay, A. E., Töx, U., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058360 · Cited by 44
Ding, Z., Wei, Y., Peng, J., Wang, S., Chen, G., & Sun, J. (2023) · Biomedicines · doi:10.3390/biomedicines11102711 · Cited by 46
Proteomic and genomic studies of non-alcoholic fatty liver disease - clues in the pathogenesis
Lim, J. W. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8325 · Cited by 40
Maurantonio, M., Ballestri, S., Odoardi, M. R., Lonardo, A., & Loria, P. (2011) · Archives of Medical Research · doi:10.1016/j.arcmed.2011.08.004 · Cited by 42
Zhu, C., Huang, D., Ma, H., Qian, C., You, H., Bu, L., & Qu, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.848937 · Cited by 47
Nutritional related liver disease: targeting the endoplasmic reticulum stress
Kammoun, H. L., Hainault, I., Ferré, P., & Foufelle, F. (2009) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32833189db · Cited by 45
Impact of Fatty Liver on Acute Pancreatitis Severity
Yoon, S. B., Lee, I. S., Choi, M. H., Lee, K. J., Ham, H., Oh, H. J., Park, S. H., Lim, C., & Choi, M. (2017) · Gastroenterology Research and Practice · doi:10.1155/2017/4532320 · Cited by 41
“Higher serum CRP levels were consistently found in fatty liver patients compared to controls in previous studies [28, 29].”
ResultChen, W., Wang, J.-B., Abnet, C. C., Dawsey, S. M., Fan, J., Yin, L., Yin, J., Taylor, P. R., Qiao, Y., & Freedman, N. D. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-1038 · Cited by 40
Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease
Alkhouri, N., Carter-Kent, C. A., Elias, M., & Feldstein, A. E. (2011) · Clinical Lipidology · doi:10.2217/clp.11.19 · Cited by 41
Controversy in the diagnosis of pediatric non-alcoholic fatty liver disease
Marzuillo, P., Grandone, A., Perrone, L., & del Giudice, E. M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i21.6444 · Cited by 37
Dairy Foods and Dairy Fats: New Perspectives on Pathways Implicated in Cardiometabolic Health
Hirahatake, K. M., Bruno, R. S., Bolling, B. W., Blesso, C. N., Alexander, L. M., & Adams, S. H. (2019) · Advances in Nutrition · doi:10.1093/advances/nmz105 · Cited by 43
“The liver is also the primary source responsible for the elevated plasma CRP concentration observed in NAFLD (79, 80).”
BackgroundSuzuki, K., Kirikoshi, H., Yoneda, M., Mawatari, H., Fujita, K., Nozaki, Y., Takahashi, H., Abe, Y., Inamori, M., Shimamura, T., et al. (2010) · Hepatology Research · doi:10.1111/j.1872-034x.2010.00643.x · Cited by 37
Self-citationShavakhi, M., Nourigheimasi, S., Dioso, E., Goutnik, M., Lucke-Wold, B. P., Khanzadeh, S., & Heidari, F. (2022) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2022/1554079 · Cited by 44
“[29, 30] In contrast, Hui and colleagues suggest hs-CRP did not accurately predict the severity of NAFLD from a histological standpoint, as they found no correlation between hs-CRP levels and grades of steatosis, fibrosis, or necroinflammation.”
ResultAkazawa, Y., Nakashima, R., Matsuda, K., Okamaoto, K., Hirano, R., Kawasaki, H., Miuma, S., Miyaaki, H., Malhi, H., Abiru, S., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0218-8 · Cited by 38
Non-alcoholic Fatty Liver Disease and Chronic Kidney Disease in Koreans Aged 50 Years or Older
Ahn, A.-L., Choi, J., Kim, M. K., Kim, S.-A., Oh, E.-J., Kweon, H.-J., & Cho, D.-Y. (2013) · Korean Journal of Family Medicine · doi:10.4082/kjfm.2013.34.3.199 · Cited by 36
Fan, Z., Li, N., Xu, Z., Wu, J., Fan, X., & Xu, Y. (2019) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2019.194412 · Cited by 35
Utzschneider, K. M., Largajolli, A., Bertoldo, A., Marcovina, S., Nelson, J. E., Yeh, M. M., Kowdley, K. V., & Kahn, S. E. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.11.007 · Cited by 36
“, 2003) have been shown to be elevated in NAFLD, with higher levels in those with steatohepatitis and fibrosis (Yoneda et al., 2007).”
BackgroundInvolvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies
Takeuchi, M., Takino, J.-I., Sakasai-Sakai, A., Takata, T., Ueda, T., Tsutsumi, M., Hyogo, H., & Yamagishi, S.-I. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i12.880 · Cited by 37
Alkhouri, N., Eng, K., López, R., & Nobili, V. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-407 · Cited by 35
“Markers, such as C-reactive protein (CRP) and fibrinogen levels, which are known to be inflammatory markers, are increased in patients with NAFLD, and particularly in those with NASH (Yoneda et al. 2007; Targher et al. 2008b).”
BackgroundPredictors of Steatohepatitis and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease
Pagadala, M. R., Zein, C. O., & McCullough, A. J. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.011 · Cited by 33
Valle‐Martos, R., Valle, M., Martos, R., Cañete, R., Jiménez‐Reina, L., & Cañete, M. D. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.629346 · Cited by 36
“Serum CRP levels are predictive of NAFLD and have been related to the presence and severity of liver fibrosis (41).”
BackgroundLeite, N. C., Salles, G. F., Cardoso, C. R. L., & Villela‐Nogueira, C. A. (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2012.01106.x · Cited by 32
Wei, H., Qu, H., Wang, H., & Deng, H. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011939 · Cited by 33
“37 hsCRP could increase in hepatocytes under the condition of steatohepatitis compared with simple steatosis.(38) Collectively, although the causal relationship between sitting time and inflammatory factors is inconclusive, we can at least hypothesise that sitting time is related to inflammatory factors, which affect…”
BackgroundASC, IL-18 and Galectin-3 as Biomarkers of Non-Alcoholic Steatohepatitis: A Proof of Concept Study
Cyr, B. S., Keane, R. W., & Vaccari, J. P. D. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228580 · Cited by 33
“High sensitivity CRP has also been tested as a serum biomarker with promising results [28,38], but as discussed above, CRP findings seem to vary across different cohorts of patients.”
BackgroundMarqués, P., Francisco, V., Martínez‐Arenas, L., Carvalho‐Gomes, Â., Domingo, E., Piqueras, L., Berenguer, M., & Sanz, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032313 · Cited by 33
“Furthermore, some observations have associated the hs-CRP levels with the severity of fatty liver [104] and the fibrosis stage [105].”
BackgroundBaldry, E. L., Aithal, G. P., Kaye, P., Idris, I. R., Bennett, A., Leeder, P. C., & Macdonald, I. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12918 · Cited by 29
A mouse model for nonalcoholic steatohepatitis
Sundaresan, S., Vijayagopal, P., Mills, N., Imrhan, V., & Prasad, C. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.08.011 · Cited by 35
“Positive correlation was found between plasma hs-CRP levels and stages of fibrosis in patients with NASH [26].”
BackgroundThe Cardiovascular Link to Nonalcoholic Fatty Liver Disease
Pacana, T., & Fuchs, M. A. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.05.008 · Cited by 33
Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk
Drapkina, O. M., & Корнеева, О. Н. (2016) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2016-12-4-424-429 · Cited by 29
Xue, J., Liang, S., Ma, J., & Xiao, Y. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-00967-y · Cited by 36
Pîrvulescu, I., Gheorghe, L., Csiki, I. E., Becheanu, G., Dumbravă, M., Fica, S. V., Martin, S., Sarbu, A. E., Gheorghe, C., Diculescu, M. M., et al. (2012) · PubMed · Cited by 31
Jamialahmadi, T., Bo, S., Abbasifard, M., Sathyapalan, T., Jangjoo, A., Moallem, S. A., Almahmeed, W. A., Ashari, S., Johnston, T. P., & Sahebkar, A. (2023) · Journal of Health Population and Nutrition · doi:10.1186/s41043-023-00372-8 · Cited by 30
Tan, C. H., Al-Kalifah, N., Ser, K., Lee, Y.-C., Chen, J., & Lee, W. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.05.024 · Cited by 31
Oda, E., & Kawai, R. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-0848 · Cited by 28
Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
Albhaisi, S., & Sanyal, A. J. (2019) · Pharmaceutical Medicine · doi:10.1007/s40290-019-00305-z · Cited by 27
“[104] 2007 hs-CRP Acute phase Reactant Predictive markers of hepatocyte injury and NAFLD progression Increased levels in NASH Yu et al.”
BackgroundJeon, D., Son, M., & Shim, J.-H. (2021) · Nutrients · doi:10.3390/nu13051720 · Cited by 30
Nonalcoholic fatty liver disease in asymptomatic Brazilian adolescents
Rocha, R., Cotrim, H. P., Bitencourt, A. G. V., Barbosa, D. B. V., Santos, A. S., Almeida, A. D. M., Cunha, B., & Guimarães, I. C. B. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.473 · Cited by 27
“The elevation of CRP in obese adults has been considered a risk factor for progression of NASH [ 31 ]”
BackgroundUddin, M. G., Hossain, M. S., Rahman, M. A., Uddin, A., & Bhuiyan, M. S. (2017) · Biological Trace Element Research · doi:10.1007/s12011-016-0919-5 · Cited by 29
Chen, J., Chou, C.-H., Tsai, W., Wang, M.-C., Ho, C.-S., Li, Y., Tsai, Y.-S., & Tsai, L.-M. (2012) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2012.04.003 · Cited by 26
“Additionally, high serum hs-CRP levels are associated with a higher grade of hepatic fibrosis in patients with NASH.(5,12) Because of these distinguishing features, we further divided patients with NAFLD by hs-CRP levels into a steatosis group (hs-CRP < median value) and a NASH group (hs-CRP > median value).”
BackgroundBrar, A. S., Khanna, T., Sohal, A., Hatwal, J., Sharma, V., Singh, C. M., Batta, A., Chandra, P., & Mohan, B. (2026) · World Journal of Cardiology · doi:10.4330/wjc.v18.i1.111954 · Cited by 30
“In summary, statins favor fatty acid oxidation, interfere with de novo lipogenesis, and prevent the progression of MASLD [255].”
Inflammatory Markers in Relation to Nonalcoholic Fatty Liver Disease in Urban South Indians
Gokulakrishnan, K., Anjana, R. M., Deepa, M., Paramasivam, P., Chandrakumar, S., Velmurugan, K., & Mohan, V. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0213 · Cited by 25
“Some studies have suggested that serum hsCRP could be used to distinguish patients with nonalcoholic steatohepatitis from those with simple steatosis.(15) The reasons for the higher serum hsCRP levels observed in NAFLD patients are still not clear, and this point needs further examination.”
Arslan, U., Kocaoğlu, İ., Balcı, M. M., Duyuler, S., & Korkmaz, A. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.05.003 · Cited by 24
Williams, K., SULLIVAN, D. R., Nicholson, G. C., George, J., Jenkins, A. J., Januszewski, A. S., Gebski, V., Manning, P. J., Tan, Y. M., Donoghoe, M. W., et al. (2015) · Metabolism · doi:10.1016/j.metabol.2015.12.008 · Cited by 25
“[40] Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, et al. High-sensitivity Creactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH.”
BackgroundHossain, I. A., Akter, S., Bhuiyan, F. R., Shah, M. R., Rahman, M. K., & Ali, L. (2016) · BMC Research Notes · doi:10.1186/s13104-016-2071-x · Cited by 26
“[25] from their observational studies reported increased levels of hsCRP can be considered the key mechanism of NAFLD development and its rapid progression to NASH due to Serum hsCRP levels (mg/l) 7 6 5 4 3 2 1 0 H O M A -IR le ve ls 8”
BackgroundKaneko, H., Anzai, T., Nagai, T., Anzai, A., Takahashi, T., Mano, Y., Morimoto, K., Maekawa, Y., Itoh, H., Yoshikawa, T., et al. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr088 · Cited by 24
Shih, K., Su, W., Chang, C., Kor, C., Chou, C., Chen, T., & Wu, H. (2016) · Scientific Reports · doi:10.1038/srep24031 · Cited by 23
Maleki, I. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i35.12566 · Cited by 22
Hepatic Steatosis Is Associated with High White Blood Cell and Platelet Counts
Chao, Y.-L., Wu, P.-Y., Huang, J., Chiu, Y., Lee, J., Chen, S., Chang, J., Hwang, S., & Chen, H. (2022) · Biomedicines · doi:10.3390/biomedicines10040892 · Cited by 25
“In addition, an increase in hs-CRP has been associated with the severity of NAFLD [58].”
BackgroundKoga, M., Murai, J., Saito, H., Mukai, M., & Kasayama, S. (2010) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2010.05.003 · Cited by 22
Tabuchi, M., Tomioka, K., Kawakami, T., MURAKAMI, Y., Hiramatsu, M., Itoshima, T., SUGAWARA, S., Kawashima, A., Okita, M., & Tsukamoto, I. (2010) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.56.271 · Cited by 23
Plasma adiponectin—an independent indicator of liver fat accumulation
Pisto, P., Ukkola, O. H., Santaniemi, M., & Kesäniemi, Y. A. (2011) · Metabolism · doi:10.1016/j.metabol.2011.03.009 · Cited by 21
“The elevation of the serum hs-CRP level has been observed in patients with NASH compared with that in those with simple steatosis [20].”
BackgroundMethodInfluentialAdvances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease
Gîlcă-Blanariu, G.-E., Budur, D. S., Mitrică, D., Gologan, E., Timofte, O., Bălan, G. G., OLTEANU, V.-A., & Ștefănescu, G. (2023) · Metabolites · doi:10.3390/metabo13111115 · Cited by 25
Liu, C., Sun, X., Peng, J., Yu, H., Lu, J., & Feng, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-52077-5 · Cited by 23
“Several studies reported that the levels of high-sensitivity C-reactive protein (hs-CRP) and inflammatory cytokines (e.g., IL-6 and TNF-α) were associated with NAFLD risk, which were considered as biomarkers of inflammation leading to endothelial cell damage 58,59 .”
BackgroundBilgir, O., Bilgir, F., Bozkaya, G., & Çalan, M. (2013) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000009 · Cited by 19
Markers in Nonalcoholic Steatohepatitis
Armutçu, F., Akyol, S., Uçar, F., Erdoğan, S., & Akyol, Ö. (2013) · Advances in clinical chemistry · doi:10.1016/b978-0-12-407680-8.00004-x · Cited by 21
Jung, S., Hwang, J., Park, S., Choi, E., Ha, K.-C., Baek, H.-I., Shin, D.-G., Seo, J., & Chae, S. (2020) · Food & Nutrition Research · doi:10.29219/fnr.v64.3517 · Cited by 19
“C-reactive protein and hs-CRP are markers of simple fatty liver and NASH, respectively (45).”
BackgroundTheel, W. B., Klerk, B. M. B., Dirksmeier-Harinck, F., van Rossum, E. F. C., Kanhai, D. A., Apers, J. A., van Dalen, B. M., de Knegt, R. J., Holleboom, A. G., Tushuizen, M. E., et al. (2022) · Obesity Reviews · doi:10.1111/obr.13481 · Cited by 22
Predicted pro-inflammatory hs-CRP score and non-alcoholic fatty liver disease
Okekunle, A. P., Youn, J., Song, S., Chung, G. E., Yang, S. Y., Kim, Y. S., & Lee, J. E. (2022) · Gastroenterology report · doi:10.1093/gastro/goad059 · Cited by 18
Evolving therapies for non-alcoholic steatohepatitis
Tilg, H., & Moschen, A. R. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.911283 · Cited by 18
“NASH patients commonly present with metabolic inflammation featured by elevated levels of C-reactive protein, ferritin, IL-6 or IL-1 receptor antagonist [14,15].”
BackgroundNonalcoholic fatty liver disease and cardiovascular disease phenotypes
Bisaccia, G., Ricci, F., Mantini, C., Tana, C., Romani, G. L., Schiavone, C., & Gallina, S. (2020) · SAGE Open Medicine · doi:10.1177/2050312120933804 · Cited by 21
Vitamin C Deficiency May Delay Diet-Induced NASH Regression in the Guinea Pig
Skat‐Rørdam, J., Pedersen, K., Skovsted, G. F., Gregersen, I., Vangsgaard, S., Ipsen, D. H., Latta, M. R., Lykkesfeldt, J., & Tveden‐Nyborg, P. (2021) · Antioxidants · doi:10.3390/antiox11010069 · Cited by 21
Yang, M., Jiang, L., Wang, Y., Li, X., Zou, Z., Han, T., Nan, Y., Lu, F., & Zhao, J. (2019) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-420 · Cited by 18
“A large number of biochemical markers related to inflammatory, apoptosis and oxidative stress have also been reported to diagnose liver fibrosis in NAFLD patients [10-12].”
BackgroundEffect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity
Carretero‐Gómez, J., Carrasco-Sánchez, F. J., Fernández-Rodríguez, J. M., Escribano, P. P. C., Miramontes‐González, J. P., Seguí‐Ripoll, J. M., Ena, J., & Arévalo‐Lorido, J. C. (2022) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2022.12.001 · Cited by 22
A crosstalk between epigenetic modulations and non-alcoholic fatty liver disease progression
Ramezani, M., Zobeiry, M., Abdolahi, S., Hatami, B., Zali, M. R., & Baghaei, K. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154809 · Cited by 16
Vallée, D., Blanc, M., Lebeaupin, C., & Bailly‐Maitre, B. (2020) · médecine/sciences · doi:10.1051/medsci/2020008 · Cited by 20
Simon, T. G., Corey, K. E., Chung, R. T., & Giugliano, R. P. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4330-z · Cited by 17
“NF-jB activation appears to play a key role both in NAFLD progression and in the development of cardiovascular disease [23].”
Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective
Ramadan, M. S., Russo, V., Nigro, G., Durante‐Mangoni, E., & Zampino, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081569 · Cited by 15
Hassoun, S., Bruckmann, C., Ciardullo, S., Perseghin, G., Gaudio, F. D., & Broccolo, F. (2022) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2022.104932 · Cited by 15
Kobayashi, T., Iwaki, M., Nogami, A., Honda, Y., Ogawa, Y., Imajo, K., Saito, S., Nakajima, A., & Yoneda, M. (2023) · Nutrients · doi:10.3390/nu15051269 · Cited by 18
“In addition, IL-6 induces C-reactive protein (CRP) production in the liver [47].”
BackgroundSelf-citationPrice, J. C., Wang, R., Seaberg, E. C., Budoff, M. J., Kingsley, L., Palella, F. J., Witt, M. D., Post, W. S., & Thio, C. L. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx153 · Cited by 17
“More importantly, sCD163, microbial translocation, and Tolllike receptor 4 signaling have been associated with fatty liver progression to NASH and fibrosis [42, 43].”
BackgroundUehara, D., Hayashi, Y., Seki, Y., Kakizaki, S., Horiguchi, N., Tojima, H., Yamazaki, Y., Sato, K., Yasuda, K., Yamada, M., et al. (2018) · World Journal of Hepatology · doi:10.4254/wjh.v10.i12.934 · Cited by 15
Wang, J.-J., Zheng, Z., & Zhang, Y. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s466469 · Cited by 14
“28,29 However, the specific mechanism of CRP elevation is unclear, and it is not certain whether CRP itself is part of the causal pathway of inflammation and cardiovascular events in the MASLD population.”
BackgroundHong, S., Lee, J. S., Kim, J. A., Lee, Y., Roh, E., Yu, J. H., Kim, N. H., Yoo, H. J., Seo, J. A., Kim, S. G., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108922 · Cited by 16
Tan, Y., Hu, Y., Yang, Y., & Chu, H. (2025) · MedComm · doi:10.1002/mco2.70532 · Cited by 15
“A key mechanism of IL-6 is its induction of the acute-phase protein CRP. High-sensitivity CRP (hs-CRP) is persistently and significantly elevated in MASH and is inex-tricably linked to the severity of liver fibrosis, serving as a reliable biomarker of systemic inflammation [231].”
Fujii, Y., Nouso, K., Matsushita, H., Kariyama, K., Sakurai, T., Takahashi, Y., Chiba, H., Hui, S., Ito, Y., Ohta, M., et al. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa044 · Cited by 14
Non-alcoholic fatty liver disease: mind the gaps: pathophysiology and non-invasive diagnosis
Verhaegh, P. L. M. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210428pv · Cited by 13
Biomarkers of Hepatic Dysfunction and Cardiovascular Risk
Lee, T. B., Kueh, M. T. W., Jain, V., Razavi, A. C., Alebna, P. L., Chew, N., & Mehta, A. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01993-5 · Cited by 16
Association between Inflammatory Biomarkers and Nutritional Status in Fatty Liver
Lim, H., Choi, J., Lee, B., Kim, S. G., Kim, Y. S., & Yoo, J. (2020) · Clinical Nutrition Research · doi:10.7762/cnr.2020.9.3.182 · Cited by 12
“sensitivity C-reactive protein (hs-CRP), an acute phase protein, is an inflammatory marker that leads to endothelial cell damage, which has also been associated with NAFLD [4].”
BackgroundWu, Y., Zheng, G., Zhang, F., & Li, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544917 · Cited by 13
Zeng, M., Chen, Y., & Zhao, B. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-1362 · Cited by 11
“CRP is an important inflammatory factor (33) and recent studies have shown it is associated with liver fibrosis and cirrhosis (34-36).”
BackgroundValle‐Martos, R., Jiménez‐Reina, L., Cañete, R., Martos, R., Valle, M., & Cañete, M. D. (2023) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-023-01434-7 · Cited by 11
Nonalcoholic Fatty Liver Disease
Dancygier, H. (2009) · Springer eBooks · doi:10.1007/978-3-642-04519-6_35 · Cited by 11
Non-Alcoholic Fatty Liver Disease: Diagnosis and Evaluation of Disease Severity
Jamali, R. (2013) · Thrita journal of medical sciences · doi:10.5812/thrita.11795 · Cited by 11
Zhao, J., Liu, J., Pang, X., Zhang, X., Wang, S., & Wu, D. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.12.026 · Cited by 11
Long, L., Liu, X., Petrick, J. L., Liu, W., Lee, J. K., Liao, L. M., Lai, M., Yang, W., Libermann, T. A., Roberts, L. R., et al. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad023 · Cited by 11
“tive protein (CRP), tumor necrosis factor (TNF)-a, and HCC risk (13,14) and CLD mortality (15-17).”
BackgroundImajo, K., Yoneda, M., Fujita, K., Kessoku, T., Tomeno, W., Ogawa, Y., Shinohara, Y., Sekino, Y., Mawatari, H., Nozaki, Y., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0776-3 · Cited by 14
“Biomarkers of oxidative stress [27, 28], inflammation [29–31], apoptosis [32, 33], and fibrogenesis [34, 35] have all been previously proposed for the diagnosis of NASH.”
BackgroundSelf-citationDietary Patterns, Foods, Nutrients and Phytochemicals in Non-Alcoholic Fatty Liver Disease
Dreher, M. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-59180-3_10 · Cited by 12
Pettersson-Pablo, P., Samyn, D. R., Wasim, J., & Vink, M. (2021) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2021.2001045 · Cited by 10
“Low-grade inflammatory activity, as measured with high sensitivity CRP (hs-CRP) methods, has been associated with risk for atherosclerosis and cardiovascular disease [14], as well as non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) [15,16].”
Noninvasive biochemical markers and surrogate scores in evaluating nonalcoholic steatohepatitis
Elsayed, A., Ismaiel, A., Procopio, A. C., Luzza, F., Abenavoli, L., & Dumitrascu, D. L. (2022) · Minerva Medica · doi:10.23736/s0026-4806.22.08185-x · Cited by 10
Attributable burden of steatotic liver disease on cardiovascular outcomes in Asia
Yin, S., Chen, Y.-T., Chang, W., Chen, T.-I., Yang, T.-H., Liu, X.-R., Huang, C.-W., Chen, Y., & Lee, M. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101479 · Cited by 14
Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease
Amacher, D. E. (2014) · Biomarkers · doi:10.3109/1354750x.2014.958535 · Cited by 10
“When Yoneda et al. (2007) measured intrahepatic mRNA expressions of high-sensitivity C-reactive protein (hs-CRP) in 100 patients with histologically verified NAFLD (29 with steatosis and 71 with NASH), the results of a multiple regression analysis revealed that in comparison with cases of…”
ResultSerum Biomarkers in Nonalcoholic Steatohepatitis: Value for Assessing Drug Effects?
Heeringa, M. J., Hastings, A. G., Yamazaki, S., & Koning, P. D. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.87 · Cited by 11
Ali, A. A., Fouda, A., Abdelaziz, E. S., Abdelkawy, K. S., & Ahmed, M. H. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002324 · Cited by 10
Can Nonalcoholic Steatohepatitis be Diagnosed Without Liver Biopsy?
Ratziu, V., Martín, L. D. O., Fedchuk, L., & Poynard, T. (2009) · Biomarkers in Medicine · doi:10.2217/bmm.09.36 · Cited by 10
Kuroda, R., Nogawa, K., Watanabe, Y., Morimoto, H., Sakata, K., & Suwazono, Y. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18062985 · Cited by 11
“Another study reported that the intrahepatic gene expression of CRP was significantly elevated in nonalcoholic steatohepatitis patients as compared with simple steatosis patients, whereas IL-6 gene expression was not, suggesting an association between increased CRP and the severity of fatty liver [15].”
BackgroundResult
Metadata
- Authors
- Yoneda, M., Mawatari, H., Fujita, K., Iida, H., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., Abe, Y., Kubota, K., Saito, S., Iwasaki, T., Terauchi, Y., Togo, S., Maeyama, S., & Nakajima, A.
- Affiliations
- Yokohama City University Hospital (JP)
- Yokohama City University (JP)
- Kitakashiwa Rehabilitation General Hospital (JP)
- ORCID
- Venue
- Journal of Gastroenterology
- Published
- 2007-07-25
- Volume
- 42
- Issue
- 7
- Pages
- 573-582
- ISSN
- 0944-1174 (ISSN-L)
- 1435-5922
- OpenAlex
- W2060798922
- Cited by
- 294
- References
- 50
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 9 · 2023: 16 · 2022: 17 · 2021: 19 · 2020: 15 · 2019: 10 · 2018: 10 · 2017: 17 · 2016: 18 · 2015: 14 · 2014: 14 · 2013: 21 · 2012: 14
- FWCI
- 14.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- high-sensitivity C-reactive protein, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, hepatic steatosis, liver fibrosis severity, interleukin-6, inflammatory markers, disease progression
- MeSH terms
- Adult, C-Reactive Protein, Fatty Liver, Female, Hepatitis, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Prospective Studies, RNA, Messenger, Severity of Illness Index, Biomarkers, Interleukin-6, Gene Expression, Logistic Models, Reverse Transcriptase Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.